USPT Rejects All Claims In Re-Exam Of Benitec, Inc. (BLT.AX)'s Patent In Response To Nucleonics Inc.'s Request For Re-Examination
2/1/2007 11:52:14 AM
HORSHAM, Pa.--(BUSINESS WIRE)--Nucleonics, Inc., a biotechnology company focused on the development of novel expressed RNA interference-based (eiRNA) therapeutics, announced today that the U.S. Patent and Trademark Office (USPTO), in response to a second request for re-examination filed by Nucleonics, has issued a second rejection of all remaining claims in Benitec’s U.S. Patent No. 6,573,099, which is the subject of litigation Benitec brought against Nucleonics in March 2004. While Benitec can appeal the recent action by the USPTO, it marks the second time in the combined re-examination proceedings that all of the Benitec patent claims have been rejected based upon prior art cited by Nucleonics and the USPTO.